[go: up one dir, main page]

MX2015017215A - Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio. - Google Patents

Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.

Info

Publication number
MX2015017215A
MX2015017215A MX2015017215A MX2015017215A MX2015017215A MX 2015017215 A MX2015017215 A MX 2015017215A MX 2015017215 A MX2015017215 A MX 2015017215A MX 2015017215 A MX2015017215 A MX 2015017215A MX 2015017215 A MX2015017215 A MX 2015017215A
Authority
MX
Mexico
Prior art keywords
sodium channel
channel inhibitors
sulfonamide compounds
compounds
bicyclic sulfonamide
Prior art date
Application number
MX2015017215A
Other languages
English (en)
Inventor
Guzman-Perez Angel
Dineen Thomas
E Marx Isaac
Weiss Matthew
Boezio Alessandro
Boezio Christiane
R Butler John
Yuhua Chu-Moyer Margaret
F Dimauro Erin
Graceffa Russell
Huang Hongbin
Kreiman Charles
La Daniel
Charles Milgrim Benjamin
Nho Nguyen Hanh
Peterson Emily
Sparling Brian
Romero Vaida Karina
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2015017215A publication Critical patent/MX2015017215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la Fórmula I, (ver Fórmula) y sales farmacéuticamente aceptables de los mismos, que son inhibidores de los canales de sodio regulados por voltaje, en particular Nav1.7. Los compuestos son de utilidad para el tratamiento de enfermedades asociadas con la actividad de los canales de sodio, tales como trastornos de dolor y picazón. También se proveen composiciones farmacéuticas que contienen a los compuestos de la presente invención.
MX2015017215A 2013-06-12 2014-06-12 Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio. MX2015017215A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361834273P 2013-06-12 2013-06-12
US201461983958P 2014-04-24 2014-04-24
PCT/US2014/042055 WO2014201206A1 (en) 2013-06-12 2014-06-12 Bicyclic sulfonamide compounds as sodium channel inhibitors

Publications (1)

Publication Number Publication Date
MX2015017215A true MX2015017215A (es) 2016-11-15

Family

ID=51063869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017215A MX2015017215A (es) 2013-06-12 2014-06-12 Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.

Country Status (9)

Country Link
US (3) US9212182B2 (es)
EP (1) EP3008057A1 (es)
JP (1) JP2016521749A (es)
AU (1) AU2014278126A1 (es)
CA (1) CA2914935A1 (es)
MX (1) MX2015017215A (es)
TW (1) TW201536768A (es)
UY (1) UY35612A (es)
WO (2) WO2014201173A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744805A1 (en) * 2011-08-17 2014-06-25 Amgen Inc. Heteroaryl sodium channel inhibitors
WO2014201173A1 (en) * 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
US20170137415A1 (en) 2014-03-29 2017-05-18 Lupin Limited Sulfonamide compounds as voltage gated sodium channel modulators
TN2017000376A1 (en) * 2015-03-02 2019-01-16 Amgen Inc Bicyclic ketone sulfonamide compounds
EP3265453B1 (en) * 2015-03-05 2022-06-29 Boehringer Ingelheim International GmbH New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
EP3331861A1 (en) * 2015-08-07 2018-06-13 Bayer Pharma Aktiengesellschaft Process for the preparation of 5-amino-quinolin-2(1h)-ones and their tautomer forms 5-amino-quinolin-2-ols
TW201722938A (zh) * 2015-09-04 2017-07-01 魯賓有限公司 作為電位閘控鈉通道調節子之磺醯胺化合物
CA3008611A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
UA122913C2 (uk) * 2015-12-18 2021-01-20 Амджен Інк. Сполуки алкілдигідрохінолінсульфонаміду
CA3008485C (en) * 2015-12-18 2023-08-01 Amgen Inc. Alkynyl dihydroquinoline sulfonamide compounds
WO2017201468A1 (en) 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7022751B2 (ja) 2016-12-09 2022-02-18 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
CN107056631A (zh) * 2017-04-14 2017-08-18 六盘水师范学院 一种基于Heck反应的2‑烯基苯胺类化合物制备方法
WO2018202524A1 (de) 2017-05-04 2018-11-08 Bayer Cropscience Aktiengesellschaft 2-{[2-(phenyloxymethyl)pyridin-5-yl]oxy}-ethanamin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel z.b. für den pflanzenschutz
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
EP3844158A1 (en) 2018-08-31 2021-07-07 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
WO2020097389A1 (en) 2018-11-09 2020-05-14 Vivace Therapeutics, Inc. Bicyclic compounds
CN109535077B (zh) * 2019-01-16 2020-09-15 上海博栋化学科技有限公司 化合物的制备方法
WO2020150474A1 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
WO2020199683A1 (zh) * 2019-04-04 2020-10-08 上海海雁医药科技有限公司 氮杂环取代的磺酰基苯甲酰胺衍生物、其制法与医药上的用途
KR102909464B1 (ko) 2019-04-16 2026-01-09 비바체 테라퓨틱스, 인크. 바이사이클릭 화합물
CN114206443B (zh) * 2019-05-10 2024-02-09 浙江海正药业股份有限公司 芳环或杂芳环类衍生物及其制备方法和用途
AU2021288190A1 (en) * 2020-06-10 2022-12-22 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
JP2021195367A (ja) * 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
EP4347583A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CN117813302A (zh) 2021-06-04 2024-04-02 沃泰克斯药物股份有限公司 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
KR20240031299A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
TW202313593A (zh) 2021-06-04 2023-04-01 美商維泰克斯製藥公司 作為鈉通道調節劑之ｎ—（羥基烷基（雜）芳基）四氫呋喃甲醯胺
AU2022326724B2 (en) * 2021-08-12 2025-10-09 Tyk Medicines, Inc. Polycyclic compound and use thereof
TW202319375A (zh) * 2021-08-19 2023-05-16 美商安進公司 用於製備丙烯酸酯化合物之無鈀方法
IL316462A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for the treatment of pain
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3256604A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
JP2026501116A (ja) 2022-12-06 2026-01-14 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの置換テトラヒドロフラン調節因子の合成のための製造方法
AU2024290917A1 (en) * 2023-07-03 2026-01-22 Resero Therapeutics, Llc Polo-like kinase 1 inhibitors
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707985A (en) 1995-06-07 1998-01-13 Tanabe Seiyaku Co. Ltd. Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators
PA8444901A1 (es) 1997-01-28 2000-05-24 Hoffmann La Roche Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
CN1315836C (zh) 2002-04-26 2007-05-16 奥索-麦克尼尔药品公司 用作雄激素受体调节剂的2－(喹诺酮基)－稠合杂环
BRPI0406778A (pt) 2003-01-17 2006-01-17 Warner Lambert Co Antagonistas de receptores de androgênio
US7009052B2 (en) * 2003-03-20 2006-03-07 Warner Lambert Company Llc Sulfonamide derivatives
NZ563186A (en) 2005-05-03 2011-09-30 Ranbaxy Lab Ltd Antimicrobial agents
CN101218235A (zh) * 2005-05-10 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
US7745629B2 (en) 2005-05-16 2010-06-29 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
EP2744805A1 (en) 2011-08-17 2014-06-25 Amgen Inc. Heteroaryl sodium channel inhibitors
WO2013086229A1 (en) 2011-12-07 2013-06-13 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
WO2014201173A1 (en) * 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors

Also Published As

Publication number Publication date
AU2014278126A1 (en) 2015-12-24
US9458152B2 (en) 2016-10-04
WO2014201173A1 (en) 2014-12-18
EP3008057A1 (en) 2016-04-20
US9212182B2 (en) 2015-12-15
JP2016521749A (ja) 2016-07-25
US20140371201A1 (en) 2014-12-18
CA2914935A1 (en) 2014-12-18
US9776995B2 (en) 2017-10-03
UY35612A (es) 2014-12-31
TW201536768A (zh) 2015-10-01
US20160046626A1 (en) 2016-02-18
WO2014201206A1 (en) 2014-12-18
US20160137636A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
MX2015017215A (es) Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
EA033689B9 (ru) Ингибиторы g12c kras
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
SA518391624B1 (ar) Ror- منظمات جاما
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
MX2015017964A (es) Inhibidores de bromodominio.
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
NZ710111A (en) Quinoline and quinoxaline amides as modulators of sodium channels
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
PH12015502365B1 (en) Bace1 inhibitors
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2018004220A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
MX378012B (es) Compuestos de alquinil dihidroquinolina sulfonamida.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
MX2018004217A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.